Boehringer Ingelheim Fremont, Inc.
About Boehringer Ingelheim Fremont, Inc.
Boehringer Ingelheim is a leading research-driven biopharmaceutical company, creating value through innovation in areas of high unmet medical need.
One of the world’s largest manufacturers of biopharmaceuticals, Boehringer Ingelheim is an industry pioneer and has produced more than 40 commercial biopharmaceuticals. Our contract manufacturing business, Boehringer Ingelheim BioXcellence™ reliably supplies innovative therapies that transform lives, today and for generations to come and creates solutions with its partners to improve patient health through its production network spanning the globe, from Biberach, Germany to Vienna, Austria, Shanghai, China and Boehringer Ingelheim Fremont Inc., in California, United States.
A mammalian cell culture center in the San Francisco Bay Area, Boehringer Ingelheim Fremont, Inc., has more than 600 scientists and specialists committed to research, development, and manufacturing to deliver high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and process intensification technology manufacturing. With the complete range of services, from cell line and strain development, including high expression systems, through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality.
Biopharmaceuticals - Competence and Experience for Medicines of the Future Over 35 years ago, Boehringer Ingelheim started developing and producing biopharmaceuticals as one of the first companies worldwide. Biopharmaceuticals are produced by using either mammalian cell cultures or microorganisms such as bacteria or yeast.
1014 articles about Boehringer Ingelheim Fremont, Inc.
-
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
7/15/2019
Acquisition adds key platform supporting Boehringer Ingelheim’s focus on patients with difficult-to-treat gastrointestinal and lung cancers
-
The M&A moves are expected to increase the oncology pipelines of both companies.
-
New data show efficacy and safety of Pradaxa® in the management of VTE in children
7/9/2019
Boehringer Ingelheim announced results from two pediatric studies of Pradaxa®, which were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia.
-
BioSpace Global Roundup: July 3
7/3/2019
Companies from across the globe provide information on agreements and pipeline updates. -
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation
7/1/2019
Boehringer Ingelheim focuses on the development of next generation NASH treatments that target all three key drivers of the disease - steatosis, inflammation and fibrosis
-
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
6/26/2019
The U.S. Food and Drug Administration has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced.
-
Arizona Care Network Partners with Solve.Care, Pharmaceutical Leader Boehringer Ingelheim To Launch Diabetes Care Administration Network
6/12/2019
New Care.Wallet app will help patients proactively address risks and symptoms of diabetes
-
Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association's 79th Scientific Sessions in San Francisco this week.
-
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
6/11/2019
Boehringer Ingelheim and University of Dundee achieve milestone in collaboration aimed at developing novel protein degradation medicines
-
Here’s a roundup of some of the top clinical trial news from the previous week.
-
Germany-based Boehringer Ingelheim announced that its SENSCIS Phase III clinical trial met its primary endpoint, which was reduction in the annual rate of decline in forced vital capacity.
-
Under the terms of the deal, AbbVie will grant Germany-based Boehringer Ingelheim a non-exclusive license for Cyltezo, its biosimilar to Humira.
-
PureTech, which has headquarters in Boston, but is listed in London, signed a research collaboration deal with Germany’s Boehringer Ingelheim. The companies will work to develop novel product candidates using PureTech’s proprietary lymphatic targeting technology for immune modulation.
-
Across the globe, pharma and biotech companies report deals and pipeline updates, with news from Boehringer Ingelheim, Metrion, Elvie, and more.
-
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
-
3BP will employ its high-diversity peptide library and hit identification technology on a set of molecular disease targets selected by Boehringer Ingelheim.
-
Messenger RNA (mRNA) is a family of RNA molecules that transport genetic information from DNA to the ribosome, where it specifies the amino acid sequence that creates proteins. In theory, by coding your own mRNA, it should be possible to insert it into the cells and turn them into protein factori...
-
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
-
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna
1/4/2019
Boehringer Ingelheim and Dicerna Pharmaceuticals announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna.
-
Xynomic Pharmaceuticals Picks up Second Cancer Drug From Boehringer Ingelheim in $800 Million Deal
12/21/2018
Xynomic Pharmaceuticals, a pharma company with roots in both the U.S. and China, forged a deal worth up to $800 million to acquire a Phase II ready cancer treatment from Germany-based Boehringer Ingelheim.